Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis

References

• Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312. doi:10.1016/s0140-6736(18)31948-2
   PubMed Web of Science ®Google Scholar
• Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369–388. doi:10.2147/ppa.S29716
   PubMed Web of Science ®Google Scholar
• Demyttenaere K. What is treatment resistance in psychiatry? A”difficult to treat” concept. World Psychiatry. 2019;18(3):354–355. doi:10.1002/wps.20677
   Web of Science ®Google Scholar
• Trevino K, McClintock SM, McDonald Fischer N, et al. Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry. 2014;26(3):222–232.
   PubMed Web of Science ®Google Scholar
• Lam RW, McIntosh D, Wang J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. disease burden and principles of care. Can J Psychiatry. 2016;61(9):510–523. doi:10.1177/0706743716659416
   PubMed Web of Science ®Google Scholar
• Muller J, Pentyala S, Dilger J, et al. Ketamine enantiomers in the rapid and sustained antidepressant effects. Ther Adv Psychopharmacol. 2016;6(3):185–192. doi:10.1177/2045125316631267
   PubMed Web of Science ®Google Scholar
• Boyer PA, Skolnick P, Fossom LH. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J Mol Neurosci. 1998;10(3):219–233. doi:10.1007/BF02761776
   PubMed Web of Science ®Google Scholar
• Borbely E, Simon M, Fuchs E, et al. Novel drug developmental strategies for treatment-resistant depression. Br J Pharmacol. 2022;179(6):1146–1186. doi:10.1111/bph.15753
   Web of Science ®Google Scholar
• Yang C, Kobayashi S, Nakao K, et al. AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine. Biol Psychiatry. 2018;84(8):591–600. doi:10.1016/j.biopsych.2018.05.007
   PubMed Web of Science ®Google Scholar
• Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi:10.1136/bmj.n160
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi:10.1136/bmj.39489.470347.AD
   PubMed Web of Science ®Google Scholar
• Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175(7):620–630. doi:10.1176/appi.ajp.2018.17060720
   PubMed Web of Science ®Google Scholar
• Ionescu DF, Fu DJ, Qiu X, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol. 2021;24(1):22–31. doi:10.1093/ijnp/pyaa068
   PubMed Web of Science ®Google Scholar
• Fu DJ, Ionescu DF, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020;81(3). doi:10.4088/JCP.19m13191
   Web of Science ®Google Scholar
• Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry. 2020;28(2):121–141. doi:10.1016/j.jagp.2019.10.008
   PubMed Web of Science ®Google Scholar
• Takahashi N, Yamada A, Shiraishi A, et al. Efficacy and safety of fixed doses of intranasal esketamine as an add-on therapy to oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. BMC Psychiatry. 2021;21(1):526. doi:10.1186/s12888-021-03538-y
   PubMed Web of Science ®Google Scholar
• Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616–630. doi:10.1093/ijnp/pyz039
   PubMed Web of Science ®Google Scholar
• Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–438. doi:10.1176/appi.ajp.2019.19020172
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Chawla JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46(7):1459–1472. doi:10.1017/S0033291716000064
   PubMed Web of Science ®Google Scholar
• Ide S, Ikeda K. Mechanisms of the antidepressant effects of ketamine enantiomers and their metabolites. Biol Psychiatry. 2018;84(8):551–552. doi:10.1016/j.biopsych.2018.07.018
   Web of Science ®Google Scholar
• Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250–256. doi:10.1016/j.biopsych.2012.06.022
   PubMed Web of Science ®Google Scholar
• Wajs E, Aluisio L, Holder R, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020;81(3). doi:10.4088/JCP.19m12891
   PubMed Web of Science ®Google Scholar
• Ceban F, Rosenblat JD, Kratiuk K, et al. Prevention and management of common adverse effects of ketamine and esketamine in patients with mood disorders. CNS Drugs. 2021;35(9):925–934. doi:10.1007/s40263-021-00846-5
   PubMed Web of Science ®Google Scholar
• Fabbri C, Hagenaars SP, John C, et al. Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. Mol Psychiatry. 2021;26(7):3363–3373. doi:10.1038/s41380-021-01062-9
   PubMed Web of Science ®Google Scholar
• Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019;19(1):247. doi:10.1186/s12888-019-2222-4
   PubMed Web of Science ®Google Scholar
• Akil H, Gordon J, Hen R, et al. Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018;84:272–288. doi:10.1016/j.neubiorev.2017.08.019
   PubMed Web of Science ®Google Scholar
• Denee T, Kerr C, Ming T, et al. Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: a retrospective database study. J Psychiatr Res. 2021;139:172–178. doi:10.1016/j.jpsychires.2021.05.026
   PubMed Web of Science ®Google Scholar
• Mrazek DA, Hornberger JC, Altar CA, et al. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr Serv. 2014;65(8):977–987. doi:10.1176/appi.ps.201300059
   PubMed Web of Science ®Google Scholar
• Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):139–148. doi:10.1001/jamapsychiatry.2017.3739
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–399. doi:10.1176/appi.ajp.2020.20081251
   PubMed Web of Science ®Google Scholar
• Sanders B, Brula AQ. Intranasal esketamine: from origins to future implications in treatment-resistant depression. J Psychiatr Res. 2021;137:29–35. doi:10.1016/j.jpsychires.2021.02.020
   Web of Science ®Google Scholar
• Palhano-Fontes F, Mota-Rolim S, Lobo-Soares B, et al. Recent evidence on the antidepressant effects of ayahuasca. In: Ayahuasca Healing and Science. Springer; 2021:21–41.
   Google Scholar
• Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655–663. doi:10.1017/S0033291718001356
   PubMed Web of Science ®Google Scholar
• Ng J, Rosenblat JD, Lui LMW, et al. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: a systematic review. J Affect Disord. 2021;293:285–294. doi:10.1016/j.jad.2021.06.032
   PubMed Web of Science ®Google Scholar
• Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542–555. doi:10.1016/j.jad.2020.09.071
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Salloum NC, Hock RS, et al. Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2020;81(4). doi:10.4088/JCP.19r12889
   Web of Science ®Google Scholar
• Bozymski KM, Crouse EL, Titus-Lay EN, et al. Esketamine: a novel option for treatment-resistant depression. Ann Pharmacother. 2020;54(6):567–576. doi:10.1177/1060028019892644
   PubMed Web of Science ®Google Scholar
• Li Z, Ruan M, Chen J, et al. Major depressive disorder: advances in neuroscience research and translational applications. Neurosci Bull. 2021;37(6):863–880. doi:10.1007/s12264-021-00638-3
   PubMed Web of Science ®Google Scholar